Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.

@article{Aydinok2015EffectsOD,
  title={Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.},
  author={Yeşim Aydinok and Antonis Kattamis and M Domenica Cappellini and Amal M El-Beshlawy and Raffaella Origa and Mohsen Saleh Elalfy and Yurdanur Kilinç and Silverio Perrotta and Zeynep Karakaş and Vip Viprakasit and Dany Habr and Niculae Constantinovici and Junwu Shen and John B. Porter},
  journal={Blood},
  year={2015},
  volume={125 25},
  pages={3868-77}
}
Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron concentrations (LIC), although some patients may require intensive chelation for a limited duration. HYPERION, an open-label single-arm prospective phase 2 study, evaluated combination DFX-deferoxamine (DFO) in patients with severe transfusional myocardial siderosis (myocardial [m] T2* 5-<10 ms; left ventricular ejection fraction [LVEF] ≥56%) followed by optional switch to DFX monotherapy when achieving mT2* >10… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS
6 Citations
32 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Impact of liver iron overload on myocardial T2* response in transfusion-dependent thalassemia major patients treated with deferasirox for up to 3 years

  • JB Porter, AT Taher, Y Aydinok
  • 2013

Similar Papers

Loading similar papers…